Key result
More sensitive cTnI cuts prolonged ED stays ~61% but increases admissions without reducing 30-day major cardiovascular events.
Why the study?
More sensitive troponin assays have the potential to better evaluate patients with suspected ACS but may lead to avoidable diagnostic testing.
Does a more sensitive cardiac troponin I assay alter resource utilization and improve clinical outcomes in patients with acute chest pain presenting to the ED?
Cohort (n=1,201)
Does a more sensitive cardiac troponin I assay alter resource utilization and improve clinical outcomes in patients with acute chest pain presenting to the ED?
Answers are grounded in this paper and cite their sources.
Implementing a more sensitive troponin assay in the ED reduced length of stay for discharged patients but increased hospitalizations and downstream procedures without significantly reducing 30-day MACE.
BACKGROUND: More sensitive troponin assays have the potential to better evaluate patients with suspected acute coronary syndrome (ACS). Meanwhile, they may result in avoidable diagnostic testing. HYPOTHESIS: Our aim was to determine the clinical impact of implementing a more sensitive cardiac troponin I (cTnI) assay in patients with acute non-traumatic chest pain presenting to the emergency department (ED). METHODS: This is a pre-post cohort study. A total of 1201 consecutive patients with acute non-traumatic chest pain or equivalent ischemic symptoms suggestive of ACS were allocated to two groups according to the cTnI assay used. The outcomes included the ED length of stay (LOS), hospital admission rate, the use of procedures and the incidence of major adverse cardiac events (MACE) at 30 days. RESULTS: The introduction of the more sensitive troponin assay shortened ED LOS (odds ratio [OR] 0.39, 95% confidence interval [CI] 0.28-0.54) regarding patients discharged home directly, increased the hospital admission rate (OR 1.43, 95% CI 1.12-1.84), the use of echocardiography (OR 1.58, 95% CI 1.22-2.06), coronary computed tomography angiography (OR 1.78, 95% CI 1.04-3.06), coronary angiography (OR 1.53, 95% CI 1.10-2.12) and percutaneous coronary intervention (OR 2.42, 95% CI 1.58-3.70) regarding patients discharged or admitted. The incidence of MACE did not decrease significantly (OR 0.61, 95% CI 0.27-1.37). CONCLUSIONS: The introduction of the more sensitive troponin assay appeared to result in less time spent in the ED regarding patients discharged home directly, but prompted more hospitalizations and procedures without impacting the incidence of MACE.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2019) conducted a cohort in acute non-traumatic chest pain or equivalent ischemic symptoms suggestive of ACS (n=1,201). More sensitive cardiac troponin I (cTnI) assay vs. Previous cTnI assay was evaluated on incidence of major adverse cardiac events (MACE) at 30 days (OR 0.61, 95% CI 0.27-1.37). Implementation of a more sensitive cardiac troponin I assay shortened emergency department length of stay but increased hospitalizations without reducing 30-day major cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: